ArticleJournal of molecular histology2026
TRIM26 triggers ferroptosis via ZEB1 degradation to suppress nasopharyngeal carcinoma progression.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although ferroptosis contributes to tumor progression, the key regulators of this process in nasopharyngeal carcinoma (NPC) remain largely unknown. TRIM26, an E3 ubiquitin ligase, has not been systematically studied in NPC or ferroptosis. Ferroptosis-related NPC genes were screened using GeneCards, FerrDb, and UbiBrowser2.0 databases. TRIM26 expression in NPC cells was determined via RT-qPCR and Western blot. TRIM26 overexpression models were established in C666-1 and NPC/HK1 cells, and a ZEB1 rescue model was further constructed in C666-1 cells. Cell viability, migration, and invasion were tested using CCK-8, wound healing, and Transwell assays. Ferroptosis was evaluated using C11-BODIPY581/591 probe, malondialdehyde (MDA), glutathione (GSH), and Fe²⁺ measurements. Co-immunoprecipitation, ubiquitination, and cycloheximide chase assays were performed to investigate TRIM26 regulation of ZEB1. Dual-luciferase reporter assays and ChIP-qPCR were conducted to verify the transcriptional regulation of SLC7A11 by ZEB1. In vivo validation was conducted using a subcutaneous xenograft model. TRIM26 was significantly downregulated in NPC cells, most markedly in C666-1 cells. TRIM26 overexpression remarkably inhibited NPC cell viability, migration, and invasion. It markedly promoted ferroptosis, with increased lipid peroxidation, elevated MDA and Fe²⁺ levels, reduced GSH content, and downregulated GPX4 and SLC7A11. Mechanistic studies revealed that TRIM26 interacted with ZEB1, promoted its ubiquitination, and accelerated its protein degradation. Furthermore, ZEB1 directly regulated SLC7A11 transcription through binding to its promoter region. ZEB1 overexpression significantly reversed the ferroptotic phenotype induced by TRIM26. In vivo, TRIM26 overexpression inhibited xenograft tumor growth and activated ferroptosis, whereas co‑overexpression of ZEB1 partially attenuated these tumor-suppressive effects. TRIM26 activates ferroptosis by promoting the ubiquitination and degradation of ZEB1 protein, thereby inhibiting NPC growth and progression. The TRIM26-ZEB1 axis may represent a potential molecular target for NPC.
Indexed as
Identifiers
42669105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.